CJC-1295 vs CJC-1295 + GHRP-6 Stack
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
CJC-1295
CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog. It stimulates the pituitary gland to release growth hormone and is almost universally used in combination with a GHRP like Ipamorelin to produce a more physiological GH pulse.
Full profileCJC-1295 + GHRP-6 Stack
CJC-1295 (GHRH analog) combined with GHRP-6 (potent ghrelin receptor agonist) to produce synergistic GH release via complementary mechanisms. GHRP-6's strong appetite stimulation distinguishes this from the CJC-1295 + Ipamorelin stack, making it preferred for bulking and mass-gaining protocols where caloric surplus is the goal. Produces larger GH pulses than CJC + Ipamorelin but with more pronounced appetite effects.
Full profile| CJC-1295 | CJC-1295 + GHRP-6 Stack | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | CJC-1295 DAC, CJC-1295 without DAC (Mod GRF 1-29), Modified GRF 1-29 | CJC GHRP-6 combination, GH releasing stack, GHRH GHRP combination, CJC-1295 GHRP-6 |
| Evidence | Research-stage | Research-stage |
| Dosing range | 100mcg–300mcg mcg, once daily (Mod GRF) or twice weekly (DAC version) | CJC-1295 100mcg + GHRP-6 100mcg–CJC-1295 200mcg + GHRP-6 300mcg mcg, 1–3x daily (pre-sleep, pre-workout, morning) |
| Administration | Subcutaneous injection (most common), Intramuscular injection | Subcutaneous injection |
| Key side effects | Water retention (especially early in protocol), Tingling or numbness in extremities, Injection site redness, Flushing (transient, shortly after injection) | Strong appetite stimulation (GHRP-6 dominant effect), Water retention, Tingling / numbness in extremities, Mild cortisol elevation (GHRP-6 is less selective than ipamorelin) |
| Cited sources | 2 references | 2 references |
Key differences
- Administration: CJC-1295 — Subcutaneous injection (most common), Intramuscular injection; CJC-1295 + GHRP-6 Stack — Subcutaneous injection.
- Frequency: CJC-1295 is typically once daily (Mod GRF) or twice weekly (DAC version); CJC-1295 + GHRP-6 Stack is 1–3x daily (pre-sleep, pre-workout, morning).
How each works
CJC-1295
Studies have demonstrated that CJC-1295 significantly increases plasma GH and IGF-1 levels. The DAC (Drug Affinity Complex) version extends the half-life to approximately 6–8 days via albumin binding, while Mod GRF 1-29 has a much shorter half-life (~30 minutes) and is dosed more acutely. Research in adults with GH deficiency has shown improved body composition and metabolic markers.
CJC-1295 + GHRP-6 Stack
The GHRH + GHRP combination synergistically amplifies GH pulse amplitude compared to either agent alone. CJC-1295 elevates baseline GH via GHRH receptor signaling at the pituitary; GHRP-6 triggers pulse timing via GHS-R1a. GHRP-6's potent appetite stimulation (significantly stronger than ipamorelin) makes this combination preferred in protocols targeting caloric surplus and mass accumulation.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.